Table 1 Univariate and multivariate Cox proportional hazard regression analysis of risk factors associated with overall survival
GSE14520 | Hazard Ratio (95% CI) | P-value |
|---|---|---|
Univariate | ||
45-gene signature (high vs. low risk) | 1.823 (1.18–2.816) | 0.00683 |
8-gene signature (high vs. low risk) | 2.36 (1.49–3.74) | 0.00026 |
Tumour size (> 5 cm vs. < 5 cm) | 2.159 (1.406–3.316) | 0.00044 |
Cirrhosis (yes vs. no) | 4.665 (1.147–18.97) | 0.0314 |
TNM staging (II and III vs. I) | 2.26 (1.706–2.994) | 1.30E−08 |
BCLC staging (B and C vs. A and 0) | 2.181 (1.722–2.762) | 9.86E−11 |
AFP (> 300 ng/mL vs. < 300 ng/mL) | 1.606 (1.049–2.46) | 0.0293 |
Multivariate (45-gene signature) | ||
45-gene signature (high vs. low risk) | 1.8864 (1.2088–2.944) | 0.00519 |
Tumour size (> 5 cm vs. < 5 cm) | 0.9487 (0.5605–1.606) | 0.8445 |
Cirrhosis (yes vs. no) | 4.5927 (1.1084–19.031) | 0.03557 |
TNM staging (II and III vs. I) | 1.4359 (1.2752–2.114) | 0.04684 |
BCLC staging (B and C vs. A and 0) | 1.7808 (1.2521–2.533) | 0.00132 |
AFP (> 300 ng/mL vs. < 300 ng/mL) | 1.4159 (0.9102–2.203) | 0.12295 |
Multivariate (8-gene signature) | ||
8-gene signature (high vs. low risk) | 1.715 (1.054–2.791) | 0.0198 |
Tumour size (> 5 cm vs. < 5 cm) | 1.1834 (0.4822–1.481) | 0.556 |
Cirrhosis | 2.820 (0.6811–11.673) | 0.1527 |
TNM staging (II and III vs. I) | 1.540 (1.178–2.383) | 0.0422 |
BCLC staging (B and C vs. A and 0) | 1.675 (1.178–2.383) | 0.00408 |
AFP (> 300 ng/mL vs. < 300 ng/mL) | 1.164 (0.7304–1.855) | 0.52297 |
TCGA-LIHC | Hazard Ratio (95% CI) | P-value |
|---|---|---|
Univariate | ||
45-gene signature (high vs. low risk) | 1.839 (1.164–2.904) | 0.008 |
8-gene signature (high vs. low risk) | 2.423 (1.51–3.89) | 0.00025 |
TNM staging (II and III vs. I) | 2.000 (1.533–2.608) | 3.14E−07 |
TP53 mutation (Yes vs. No) | 2.484 (1.485–4.155) | 5.30E−04 |
CTNNB1 mutation (Yes vs. No) | 1.894 (1.084–3.311) | 0.025 |
Multivariate (45-gene signature) | ||
45-gene signature (high vs. low risk) | 1.606 (1.014–2.542) | 0.03329 |
TNM staging (II and III vs. I) | 1.879 (1.434–2.461) | 4.65E−06 |
TP53 mutation (Yes vs. No) | 2.150 (1.271–3.635) | 0.0043 |
CTNNB1 mutation (Yes vs. No) | 1.553 (0.884–2.726) | 0.13 |
Multivariate (8-gene signature) | ||
8-gene signature (high vs. low risk) | 2.229 (1.388–3.580) | 0.000914 |
TNM staging (II and III vs. I) | 1.865 (1.428–2.434) | 4.63E−06 |
TP53 mutation (Yes vs. No) | 1.939 (1.158–3.246) | 0.012 |
CTNNB1 mutation (Yes vs. No) | 1.917 (1.085–3.385) | 0.025 |
LIRI-JP | Hazard Ratio (95% CI) | P-value |
|---|---|---|
Univariate | ||
45-gene signature (high vs. low risk) | 2.671 (1.361–5.240) | 0.00328 |
8-gene signature (high vs. low risk) | 3.45 (1.69–7.04) | 0.00067 |
Fibrosis (yes vs. no) | 1.024 (0.8155–1.286) | 0.838 |
Tumour size (> 3 cm vs. < 3 cm) | 2.415 (1.263–4.615) | 0.00764 |
Portal vein invasion (yes vs. no) | 2.281 (1.712–3.039) | 2.00E−08 |
Hepatic vein invasion (yes vs. no) | 1.822 (1.112–2.985) | 0.0173 |
Bile duct invasion (yes vs. no) | 1.392 (0.987–1.963) | 0.059 |
TNM staging (II and III vs. I) | 2.267 (1.556–3.304) | 2.03E−05 |
Multivariate (45-gene signature) | ||
45-gene signature (high vs. low risk) | 2.201 (1.112–4.357) | 0.0236 |
Tumour size (> 3 cm vs. < 3 cm) | 1.471 (0.746–2.898) | 0.265 |
TNM staging (II and III vs. I) | 2.009 (1.348–2.995) | 0.000617 |
Multivariate (45-gene signature) | ||
45-gene signature (high vs. low risk) | 2.286 (1.139–4.587) | 0.02 |
Portal vein invasion (yes vs. no) | 2.314 (1.635–3.275) | 2.19E−06 |
Hepatic vein invasion (yes vs. no) | 0.843 (0.462–1.539) | 0.579 |
Multivariate (8-gene signature) | ||
8-gene signature (high vs. low risk) | 2.578 (1.228–5.412) | 0.0123 |
Tumour size (> 3 cm vs. < 3 cm) | 1.386 (0.698–2.752) | 0.3513 |
TNM staging (II and III vs. I) | 1.878 (1.268–2.781) | 0.00167 |
Multivariate (8-gene signature) | ||
8-gene signature (high vs. low risk) | 2.419 (1.141–5.129) | 0.0213 |
Portal vein invasion (yes vs. no) | 2.057 (1.449–2.920) | 5.40E−05 |
Hepatic vein invasion (yes vs. no) | 0.914 (0.508–1.646) | 0.765 |